British Doctors Will Start New Phase III Trial with Pharmexa Inc.'s GV1001 Vaccine

London, England -- Pharmexa, the Danish-based biotech company, announces that British Doctors are to start a new phase III trial with Pharmexa's GV1001 vaccine. This is the largest ever trial to test a new vaccine for pancreatic cancer. The study will be conducted at centres across the UK and plans to enroll over 1100 patients.

The trial is designed and managed by the Pancreas Cancer Sub-group of the National Cancer Research Institute in the UK, with Dr. Gary Middleton of the Royal Surrey County Hospital as Chief Investigator

The group of Principal Investigators include Professor David Cunningham of the Royal Marsden Hospital and Professor John Neoptolemos of the Royal Liverpool University Hospital.

Pancreatic cancer is a rare but very serious disease, which affects approximately 7,000 people a year in the UK. These patients generally have a poor prognosis, and only about 15% of patients are alive a year after being diagnosed with the disease. Pancreatic cancer is currently mainly treated with chemotherapy, and unfortunately with limited effect.

For more information, please contact Mary Clark or Halina Kukula, Capital MS&L on Tel: 020 7307 5336.

>>> Discuss This Story